## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)													
1. Name and Address of Reporting Person * VANCE DOLLY				I	2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				4400	3. Date of Earliest Transaction (Month/Day/Year) 09/13/2012					X Officer (give title below) Other (specify below)  EVP Corp. Affairs, G.C., Sect.					
(Street) SOUTH SAN FRANCISCO, CA 94080					4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City	)	(State)	(Zip	))	Т	able I - No	n-D	erivative	Securi	ties Acq	uired, Disp	osed of, or I	Beneficially	Owned	
(Instr. 3) Date			2. Transacti Date (Month/Day	y/Year) Ex	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)		4. Securities Acquired (or Disposed of (D) (Instr. 3, 4 and 5)		(D)	(A) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Following	Ownership o Form: B	7. Nature of Indirect Beneficial
			(IVI	Code		V	Amount	(A) or (D)	Price		or (I		\ /	Ownership (Instr. 4)	
Common	Stock		09/13/201	12		S		4,151	D	\$ 10.427	1,103			D	
			T				the ed, l	form di Disposed	splays	s a curre Beneficia	ently valid	uired to res I OMB cont	•		
1. Title of Derivative Conversion Security (Instr. 3) Price of Derivative Security 3. Transact Date (Month/Date (Month/Date Security)		ion 3A. Deemed Execution Da any		e, if Transaction Number and Expiration Date Code of (Month/Day/Year) Amount of Underlying S				8. Price of Derivative Security (Instr. 5)	Derivative Securities  Derivative Securities	Ownersl Form of Derivati Security Direct (I or Indire	Ownership (Instr. 4)				
					Code V	(Instr. 3, 4, and 5)	Da Ex	nte ercisable	Expira Date	ation Tit	Amount or Number of Shares		(maa: 1)	(msu. 1)	
Repor	ting O	wners								,					
						Relation	ship	os							
Pen	orting Own	r Name / Ac	ldress		100/										

		Relationships						
Reporting Owner Name / Address		Director	10% Owner	Officer	Other			
	VANCE DOLLY RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			EVP Corp. Affairs, G.C., Sect.				

## **Signatures**

/s/ Dolly Vance	09/14/2012			
**Signature of Reporting Person	Date			

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.